192699-42-6

Basic information

• Product Name: 4-BROMO-3'-CYANOBIPHENYL
• Synonyms: 4-BROMO-3'-CYANOBIPHENYL;4'-bromo-[1,1'-biphenyl]-3-carbonitrile
• CAS NO: 192699-42-6
• Molecular Formula: C₁₃H₈BrN
• Molecular Weight: 258.11
• Product Categories: pharmacetical
• Mol File: 192699-42-6.mol

Chemical Properties

• Boiling Point: 373.9°Cat760mmHg
• Flash Point: 179.9°C
• Appearance: /
• Density: 1.48g/cm³
• CAS DataBase Reference: 4-BROMO-3'-CYANOBIPHENYL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3'-CYANOBIPHENYL(192699-42-6)
• EPA Substance Registry System: 4-BROMO-3'-CYANOBIPHENYL(192699-42-6)

Safety Data

• Hazardous Substances Data: 192699-42-6(Hazardous Substances Data)

Usage

Uses

Used in Liquid Crystal Display (LCD) Industry:
4-Bromo-3'-cyanobiphenyl is used as a starting material for the synthesis of various liquid crystal materials, primarily for the production of liquid crystal displays (LCDs). Its mesogenic properties enable the formation of liquid crystal phases, which are essential for the functioning of LCDs.
Used in Organic Electronics:
4-Bromo-3'-cyanobiphenyl has also been investigated for its potential applications in organic electronics due to its unique chemical structure and properties. Its use in this field is still under research, but it holds promise for future advancements in electronic devices and materials.
Safety Precautions:
It is important to handle 4-Bromo-3'-cyanobiphenyl with care, as it is considered hazardous. Exposure to this chemical may cause irritation to the skin, eyes, and respiratory system. Proper safety measures, such as wearing protective gear and working in a well-ventilated area, should be taken to minimize potential health risks.

Upstream product

• 589-87-7 1,4-bromoiodobenzene 
• 150255-96-2 (3‐cyanophenyl)boronic acid 

Downstream Products

• 1565857-82-0 4'-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-biphenyl-3-carbonitrile 

Relevant articles and documents

BIMESOGENIC COMPOUNDS AND MESOGENIC MEDIA

The invention relates to bimesogenic compounds of formula Iwherein R 11 , R 12 , MG 1 , MG 2 , X 11 , X 12 and Sp 1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and in particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1 and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula 1, and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).